{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Effect&page=2",
    "query": {
      "condition": "Drug Effect",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Effect&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:04:53.841Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003269",
      "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lung Cancer",
        "Lymphoma",
        "Ovarian Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Scripps Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "1998-02",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2011-01-10",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003269"
    },
    {
      "nct_id": "NCT03299556",
      "title": "Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "WHT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 420,
      "start_date": "2017-10-05",
      "completion_date": "2019-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Danville, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03299556"
    },
    {
      "nct_id": "NCT05797753",
      "title": "A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "SAR443820",
          "type": "DRUG"
        },
        {
          "name": "Erythromycin ethyl succinate",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2022-02-18",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797753"
    },
    {
      "nct_id": "NCT02864953",
      "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Edema",
        "Stroke, Acute"
      ],
      "interventions": [
        {
          "name": "BIIB093",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Remedy Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 535,
      "start_date": "2018-08-29",
      "completion_date": "2023-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 74,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02864953"
    },
    {
      "nct_id": "NCT02104739",
      "title": "Effects of Antidiabetic Medications on the Postprandial State in Prediabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prediabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Exenatide extended-release (ER)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 21,
      "start_date": "2014-04",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02104739"
    },
    {
      "nct_id": "NCT01660477",
      "title": "Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of Isavuconazole",
        "Pharmacokinetics of Lopinavir/Ritonavir",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Isavuconazole",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-06",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-23",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660477"
    },
    {
      "nct_id": "NCT06970223",
      "title": "A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir long-acting",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir long-acting",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2025-04-22",
      "completion_date": "2026-07-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06970223"
    },
    {
      "nct_id": "NCT02222441",
      "title": "Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Palbociclib alone",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib plus Modafinil",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib plus pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2014-10",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-20",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222441"
    },
    {
      "nct_id": "NCT03605966",
      "title": "Developing a Method to Objectively Measure Opioid Analgesia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Julia Finkel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "7 Years to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2018-07-01",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03605966"
    },
    {
      "nct_id": "NCT01681095",
      "title": "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Ischemia",
        "Coronary Disease",
        "Heart Diseases",
        "Valvular Heart Disease"
      ],
      "interventions": [
        {
          "name": "Custodiol HTK",
          "type": "DRUG"
        },
        {
          "name": "Cold Blood Cardioplegia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marc Sakwa, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2012-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-05-22T09:04:53.841Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681095"
    }
  ]
}